presentation materials

VTT TECHNICAL RESEARCH CENTRE OF FINLAND LTD
Creating bioeconomic
growth
Prof. Dr. Antti Vasara
President & CEO, VTT
June 2nd, 2016
Finland lives from research and innovation
Note: Figures are
from 2013
03/06/2016
2
VTT Technical Research Centre of
Finland Ltd
 A leading R&D organisation
in Nordic countries
 We provide expert services
for our domestic and
international customers
and partners, both in
private and public sectors
TOP 2
VTT is second
most active
patenting
organisation in
Finland (2014)
36%
of Finnish
innovations
include VTT
expertise
We use
4 million
hours
of brainpower a
year to develop
new technological
solutions
Net turnover and other operating
income 272 M€ for VTT Group in 2015
Personnel 2,470
(VTT Group 31.12.2015 )
(VTT Group’s turnover 185 M€ in 2015)
Unique research and testing
infrastructure
3.6.2016
Wide national and international
cooperation network
3
Ray Kurzweil:
Three technologies that will define our future
1
3
The genetics revolution will
allow us to REPROGRAM
OUR OWN BIOLOGY
The robotics revolution will
allow us to CREATE A
GREATER THAN HUMAN
NON-BIOLOGICAL
INTELLIGENCE
2
The nanotechnology
revolution will allow us to
MANIPULATE MATTER AT
THE MOLECULAR AND
ATOMIC SCALE
Pace is accelerating today’s best tools will
help us build even better
tools tomorrow.
Source: Ray Kurzweil http://www.singularityhub.com/2016/04/19/ray-kurzweil-predicts-three-technologies-will-define-our-future/
03/06/2016
4
Bioeconomy’s significance for Finland
Turnover
€ 64bn
Share of
employment
11%
Share of
exports
26%
03/06/2016
Finland seeks to increase its bioeconomy
output to 100 billion euros by 2025 and
to create 100,000 new jobs
in the process.
Bioeconomy combines
wood processing, chemistry,
energy, construction, technology,
food and health.
Forest based bioeconomy
accounts for two thirds.
5
Combining different
technologies together
KNOWLEDGE
INTENSIVE
PRODUCTS AND
SERVICES
SOLUTIONS FOR
NATURAL
RESOURCES
AND
ENVIRONMENT
SMART INDUSTRY
AND ENERGY
SYSTEMS
03/06/2016
6
VTT’s R&D infrastructure – an essential part
of the national research infrastructure
03/06/2016
3.6.2016
7
TECHNOLOGY FOR BUSINESS
Industrial Biotechnology – an enabler of Bioeconomy
Prof. Merja Penttilä
03/06/2016
Living Factories
Creating Bioeconomic Growth–
Industrial Biotechnology Business Seminar
Espoo, Finland 2.6.20161
Living Factories – Synthetic biology for a sustainable
bioeconomy
2014-2019
03/06/2016
•
•
•
•
VTT Technical Research Centre of Finland, Merja Penttilä
Aalto University, Markus Linder
University of Turku, Eva-Mari Aro
2
Innomedica, Tanja Dowe
CO2
03/06/2016
3
CO2
Biotechnology as an enabler
ENZYME
MICROBE
03/06/2016
4
Is it a technology?
Yes, beer and wine...
but don’t they brew by
themselves?
President Sauli Niinistö congratulates the
2016 winner of the Finnish Millenium
Technology Prize, Frances Arnold (CalTech,
USA), for her work on directed evolution.
03/06/2016
•
Directed evolution of industrial enzymes
was already practised in Finland in early
1990’s
•
Enzyme companies operating in Finland
have used directed evolution extensively
•
Large part of Roal’s enzymes are mutants,
e.g. thermostable phytase and cellulases
5
Can it deliver?
•
Biotechnology is suited for large and small scale
•
•
Production levels can be >> 100 g / liter enzymes
>> 150 g/ liter chemicals, with yields of 30-95%
•
Production can be improved 10-1000-fold
(don’t jugde what is achievable based on the capability of
natural organisms)
Baker’s yeast
cell volume ~ 40 µm3
Fermentation tanks
can be 1 million m3
03/06/2016
6
Biotechnology can provide many
platform chemicals
Ethanol
Isobutanol
nButanol
1,3Propanediol
Lactic
acid
Itaconic
acid
Succinic
acid
Acetic
acid
In production
(TRL 8-9)
Isobutene
Isoprene
Farnesene
1,4Butanediol
Putrescine
Fumaric
acid
Glutaric
acid
Isobutyric
acid
Acetone
Styrene
Cadaverine
Malic
acid
4-Hydroxy
Butyric
acid
Butyric
Acid
nPropanol
Phenyl
acetic acid
Hexamethylenediamine
Xylonic
acid
Adipic
acid
Xylitol
Isopropanol
4-Hydroxy
styrene
4-Aminobutyric
acic
Muconic
acid
Glucaric
acid
Sorbitol
1,2,4Butanetriol
4-Hydroxy
benzoic acid
5-Aminovaleric
acid
Galactaric
acid
Glykolic
Acid
Monoethylene
glycol
Terpenoids
Phenol
1,3Butadiene
Malonic
acid
Propionic
acid
LGalactonic
acid
Polyhydroxy
alkanoates
Propane
Acrylic
acid
Fatty
acids
Fatty
alcohols
Adipic
acid
Polyhydroxy- 3-Hydroxybutyrate
propionic(PHB)
acid
Piloting (TRL 5-7)
Research (TRL 1-4)
Feasibility of production has been shown for many new
chemicals.
The picture does not include specialty chemicals
03/06/2016
and drugs, which also can be produced biotechnologically
7

Production of therapeutic human antibodies with
filamentous fungi

Spider silk produced by microbes

Production of glycolic aciid by yeast and its polymerisation into a bioplastic with good barrier
properties

Many examples of feasibility of metabolic engineering
for chemical and fuels production with microbes,
including photosynthetic organisms
2010’s
2000’s
1990’s

Production of rare sugars with microbes

A yeast that produces lactic acid, enabling a costeffective process for production of PLA

Yeast and filamentous fungi that produce sugar acids
at low pH from biomass sugars

Thermotolerant industrial enzymes

Biotechnological production of xylitol

Pentose utilising baker’s yeast for bioethanol
production from lignocellulosics

Efficient hydrolytic enzyme mixtures and their
production processes

Enzyme-aided bleaching of pulp

Engineered antibodies for diagnostic purposes

Production of bioactive compounds with
Sreptomycetes

Production of alkaloids with plant cells

Human collagen produced by yeast

Improvement of filitration of beer with yeast that
produces endoglucacase enzyme that hydrolyses glucan
originating from barley

A brewer’s yeast that does not produce buttery flavour,
and thus the step of secondary fermentation can be
omitted in beer production

Yeasts that produce amylolytic and cellulolytic enzymes
for production of alcohol in a consolidated process

New DNA cutting restriction enzymes in production
1980’s
Finland has been pioneering
in biotechnology
The achievements
are relevant for today’s
Bioeconomy
We can now improve
through ”synthetic biology”
The DBTL cycle
of Synthetic Biology
DESIGN
BUILD
Hundreds of
engineered
strains can be
tested in a
week
LEARN
TEST
Construction of production strains will
become >10-fold faster and cheap
03/06/2016
9
The DBTL cycle
of Synthetic Biology
DESIGN
BUILD
Design
Construction of
production strains
Production strains and
their parts are designed
using computational
tools
Analysis and
decisions
Hundreds of
engineered
strains can be
tested in a
week
LEARN
Machine learning algorithms
can help the researcher to
analyse and understand
measured data.
03/06/2016
Synthetic DNA is delivered
to the cells using genome
editing tools such as CRISPR.
TEST
Cultivation and
measurement
Robots are cultivating the
strains and carry out measurements. The results are automatically stored in databases.
10
Automated strain engineering
Computational recepies
for the robot to carry
out Build and Test phases
Full automation of
strain construction
and cultivation
DESIGN
BUILD
Design
Construction of
production strains
Production strains and
their parts are designed
using computational
tools
Analysis and
decisions
Hundreds of
engineered
strains can be
tested in a
week
LEARN
Machine learning algorithms
can help the researcher to
analyse and understand
measured data.
03/06/2016
Synthetic DNA is delivered
to the cells using genome
editing tools such as CRISPR.
TEST
Cultivation and
measurement
Robots are cultivating the
strains and carry out measurements. The results are automatically stored in databases.
11
Natural synthesis power
Evolution power
Reaction specificity
>> 6000 genes
>> 1000 (bio)chemical reactions
Vast variety of
material structures
Natural synthesis power
Evolution power
Reaction specificity
CO2
FEEDSTOCK
>> 6000 genes
>> 1000 (bio)chemical reactions
Vast variety of
material structures
A single unit operation
Mild conditions
PRODUCTS
Natural synthesis power
Evolution power
Reaction specificity
Heterogenous
FEEDSTOCK
PRODUCT
Growth
A single unit operation
Mild conditions
Natural synthesis power
Evolution power
Reaction specificity
FEEDSTOCK
PRODUCTS
SYNTHETIC BIOLOGY
Design of cell factories based on mathematical cell models
Automated construction and high through-put selection of production strains
New reactions, new products, more efficient production processes
Living Factories Synthetic biology for a sustainable bioeconomy
1.
Develop genome engineering and automation technologies that will make design and
construction of Living Factories predictable, cheap and fast
 Lowered barrier for Finnish industry to use biotechnology
2.
Establish novel cellular chemistries ”from C1 to Cn”
 new products for chemical and energy industries that are difficult to make chemically (or
biotechnically
3.
Create Synthetic Living Factories that are most carbon and energy efficient
 Sustainable processes for bioeconomy
4.
Establish an international and dynamic business-research-education environment based of
Synthetic Biology  courageous new generation of experts with novel business ideas
What are the possibilities and
challenges in biotechnology?
What is the path forward?
How to diversify Finnish
bioeconomy?
Thank you!
03/06/2016
17
What is the position of industrial
biotechnology in our global future?
Adam M. Burja
Agenda
•
•
•
•
•
•
•
Some Background
The basis for modern industry is carbon
What can biotechnology do?
Contributes to the Carbon Initiative
A positive effect on the economy
A perspective from multi-national companies
The future is bright
Industrial Biotechnology
• The application of biotechnology for industrial purposes, including
manufacturing, alternative energy, and biomaterials. It includes the
practice of using cells or components of cells like enzymes to
generate industrially useful products
• A transformative process that uses the tissues, cells, genes or
enzymes of plants, algae, marine life, fungi or micro-organisms
• An activity that uses a biotechnological process to produce and
process materials, chemicals and energy
Market Research
• Biotechnology industry has mushroomed since 1992
• Worldwide Revenue ($bn):
– 216.5 (2011); 270.5 (2013); 323 (2015); 414.5 (2017)
•
•
•
•
3.7% growth from 2011-2016 (CAGR 12.3%)
Industry current employs 564,000 people globally
7,000 companies globally (2,500 in the US)
One of the most research-intensive industries in the
world. US biotechnology industry spent $35.4bn on
R&D in 2014
Market Research
• Capital raised by leading US regions vs Capital raised
by leading European countries (2015)
US Regions
European Countries
Graphs plot venture capital investment against innovation capital (defined as
money raised by companies with less than $500m revenues, including private
firms and therefore positively correlated to venture capital)
The basis for industry is carbon
• Modern industry uses the stored energy from sunlight
first captured by plants through photosynthetic as…
– Petroleum derivatives; or
– Carbohydrates (e.g. cellulose, sucrose, glucose); or
– Waste products (e.g. C1s: CO2, CO, syngas, CH4)
• Cost driver is petroleum and sugar (sucrose) prices
Biotechnology can be used to
develop…
– new products,
– replace key industry intermediates
• NREL Top Value Added Chemicals from
Biomass
– make existing products more
efficiently
• cheaper, better, cleaner, faster, etc.
Industries that utilize biotechnology
Biotechnology helps contribute to
lowering carbon footprint
• PARIS 2015 COP21 Climate Change Conference
• Countries set a goal to limit global warming to less
than 2°C compared to pre-industrial levels by the
end of the 21st century
• Legally binding on 22 April 2015
• Agreement encourages:
– climate action by governments to enable a shift to a lowcarbon economy and
– helps drive concrete actions, to reduce the carbon
footprint
• Companies that embrace CSR are on average 36%
more profitable than those that don’t
Recent advances in biotechnology
• Synthetic Biology – Enabled by:
– Miniaturization and automation
– Development of new methods for
synthesis and manipulation of DNA
• Gene and genome editing technologies
such as MAGE, CRISPR-Cas9, TALEN, Zincfingers and novel nucleic acid synthesis
technologies
Recent advances in biotechnology
• Several countries have embraced
this technology:
– United States:
• Synberc
• DARPA 1,000 molecules initiative
– United Kingdom:
• A Synthetic Biology Roadmap for the UK
– Canada
– Others…
Recent advances in biotechnology
• Established industries have also biotechnology in
general and synthetic biology in particular
Established industries have also
embraced biotechnology in general
and synthetic biology in particular
Case Study: Big Five Petroleum companies:
– The low oil prices creates new opportunities and challenges
for energy innovation.
– Yet in this environment all multi-nationals have maintained
or even continued to invest in Bioscience / Biotechnology /
Bioindustrial capabilities.
– Seen as disruptive technology in the field
– In this environment, BP’s technology is focused on applying
ready-to-go technologies everywhere they are needed,
helping the businesses to be safer, smarter and faster.
Case Study:
• Since 2006, BP has invested over $4b in Alternative Energy Options
• Develop low carbon transportation fuels not linked to petroleum market
• In 2010 hired ‘Global Synthetic Biology Manager’ and acquired Diversa
(San Diego) and four Sugar Cane Ethanol Facilities (Brazil)
• In 2014 decision was taken to exit the Lignocellulosic ethanol biofuels
business.
• In 2015 established a Biosciences Center to sustain critical mass in
biosciences capability, perfect current opportunities and assess future
opportunities across BP’s businesses
• Recently completed the construction of a
purpose-built mixed laboratory and office site
in San Diego.
Case Study:
• DSM – Bright Science. Brighter Living
• Royal DSM is a global science-based
company active in health, nutrition
and materials
• Uses biotechnology and material sciences to drive economic
prosperity, environmental progress and social advances
• Strong commitment to social responsibility:
– CEO recently named co-chair of the Carbon Pricing Leadership Coalition
– A group launched at Paris COP21 in December 2015.
– The initiative aims to put a price on carbon emissions.
The future is bright
• Industrial biotechnology provides a means to:
– Increase economic output
– Provide highly-skill, high-paying employment in the private
sector
– Enable a shift towards a bio-based economy. One based on a
production paradigm that relies on biological processes
– Develop new and more efficient means of production which
expend minimum amounts of energy
– Reduce greenhouse emissions in production and energy
generation
– Minimize the production of waste as all materials discarded by
one process are inputs for another
– Realize low cost, secure energy
Investing in industrial biotechnology –
why & what
Doug Cameron
First Green Partners
Aalto Design Factory
Finland
June 2, 2016
First Green Partners and a quick biosketch
Perspectives on industrial biotechnology investment
• Significance
• Areas
• Criteria
Some representative examples
First Green Partners
What: Early-stage venture fund
Nature's first green is gold,
Her hardest hue to hold.
Headquarters: Minneapolis
from “Nothing Gold Can Stay”
by Robert Frost
Investment focus: Sustainable agriculture, food, energy,
and materials
Investment region: USA and Canada
A quick biosketch
Advanced Harvesting Systems, first job out of
college
Agricultural/industrial bio startup (large-scale
protein separatation)
MIT, graduate school
Microbial production of R-1,2-propanediol (chiral
propylene glycol)
Department of Chemical Engineering, UW-Madison
Microbial production of 1,3-propanediol
Began work on 3-hydroxypropionic acid (route to
bio-based acrylic acid)
A quick biosketch (continued)
Cargill
lactic acid, polylactic acid
acrylic acid
non-caloric sweeteners
Khosla Ventures
Isobutanol, Gevo (Frances Arnold)
fatty acids, LS9
ethanol, Lanzatech
First Green Partners
amino acids, Trelys
Cargill/NatureWorks Polylactic
Acid (PLA)
OH
O
O
O
O
OH
O
L,L-lactide
D,L-lactide
D,D-lactide
Mainly L-lactic
O
CH3
CH3
O
OH
HO
O
O
CH3
O
n
co-op communications
Lactic acid processes: Cargill/NatureWorks
pH > 4.5 (Traditional fermentation, Lactic acid bacteria)
Lactic
acid
+
Ca(OH)2
Calcium
lactate
+
Lactic
acid
+
H2SO4
CaSO4
pH < 3.0 (Novel process, Engineered yeast)
Lactic
acid
extractant
Finland Connection
VTT
Sisu
Pirkko Suominen
Lactic
acid
Cargill Erythritol
Biorefinery
BLAIR, NEBRASKA
Cargil Lactic Acid Plant
NW Polymer Plant
Missouri River
Evonik (lysine)
Cargill Ethanol
Cargill Sugar Refinery
Cargill Corn Mill
Cargill Corn Oil
10
650acres - 1 square mile-2.6 sq km-256 hectares
A quick biosketch (continued)
Cargill
lactic acid, polylactic acid, VTT connection,
Sisu
acrylic acid
non-caloric sweeteners
Khosla Ventures
Isobutanol, Gevo (Frances Arnold)
fatty acids, LS9
ethanol, Lanzatech
First Green Partners
amino acids, Trelys
Why invest in industrial biotechnology?
From a business stand-point, the only reason to invest is to make a return on
invested capital (ROIC)
Otherwise, it is philanthropy (a gift)
------------------------------------------------------------------------------However, there is a spectrum from high to low returns
Impact investors are open to making lower returns for greater environmental and
social impact
Industrial biotechnology can have a positive enviromental and social impact
Our goal is investments with high returns
PLUS
positive impact
Sustainable business
Technical
Technical
Financial
Financial
Social
Environ
The what: Areas for industrial biotechnology investment
Fuels and commodity chemicals
Tough for venture capital
Government grants and programs (EU, Climate KLIC)
Private foundations (Breakthrough Energy)
Large strategics (Total, Exxon, BASF, UPM, Stora Enso)
Specialty chemicals/materials/agricultural chemicals
Some venture capital interest
Some family office/Impact interest
Some strategic interest
Food and food ingredients
Significant venture capital interest
Good Impact interest
Good large strategic interest (General Mills, others)
New effort led by Bill Gates
Selected members:
3M
AkzoNobel
BASF
Beierdorf AG
Eastman Chemical
HP
Johnson & Johnson
Nike
Procter and Gamble
SABIC
Unilever
Walmart
The what: Areas for industrial biotechnology investment
Fuels and commodity chemicals
Tough for venture capital
Government grants and programs
Private foundations (Breakthrough Energy, KLIC)
Large strategics (Total, Exxon, BASF, UPM, Stora Enso)
Specialty chemicals/materials/agricultural chemicals
Some venture capital interest
Some family office/Impact interest
Some strategic interest
Agriculture and food
Significant venture capital interest
Good Impact interest
Large strategics (Bayer, Unilever, Nestle, General Mills)
Ag and food
… some have estimated that it will take as much
innovation in agriculture in the next forty years as in the
preceding 10,000 years if we're to meet the demand for
food.
Tom Vilsack
U.S. Secretary of Agriculture
Source:http://www.usda.gov/wps/portal/usda/usdahome?contentid=2015/07/0194.xml&navid=TRANSCRI
PT&navtype=RT&parentnav=TRANSCRIPTS_SPEECHES&edeployment_action=retrievecontent
Ag and food (cont.)
… over the past 10 years, we have made more
progress incorporating food and tech than in
the previous 1,000 years. Just two decades
from now, your food life might be
unrecognizable from the way it is today.
... it’s only going to get more interesting as our
food world changes at such a rapid pace.
Andrew Zimmern, host of Bizarre Foods, in Delta Sky,
April 2016
Key considerations for early-stage technology investment
Open minded to all early-stage technologies as
long as they do not violate the
Laws of Thermodynamics
For an existing chemical, must have a route to
be at least 30% cheaper than best available
technology
For a new chemical or product, must offer a 35x advantage over current solution
How do companies meet previous considerations?
Advantaged feedstock (biomass, CO2, H2 tailgas)
High yields on feedstock
Unique product (function, taste, purity, reactivity)
Fast development cycle
Some example companies and technologies
Use of supercritical water to deconstruct wood and other biomass to:
C5 sugars, C6 sugars, and high-quality reactive lignin
Working with UPM, BASF, and Total
(Germany)
(Texas)
Methane
(Biogas)
X
Anerobic
digestion
Organic acids
Waste biomass
Chemical
tranformation
Fuels, commodity chemicals
Specialty chemicals
Malonate: A commodity chemical “sleeping giant”?
Malonic acid
2/3 C6H12O6 + 2 CO2 ---> 2 C3H4O4
Y = 1.73 g malonic acid/g glucose
CHO
H2 “tailgas” to feed amino acids and other products
(using engineered methanogenic archea)
Yeast-produced silk proteins
Steviol
Stevioside
Use heme produced by yeast fermentation
Leather produced in animal cell culture
A personal foundry?
CREATE: CRISPR EnAbled Trackable genome Engineering
Ryan Gill (CU-Boulder), Zhiwen Wang (Tianjin), et al.
Thank you
Doug Cameron
[email protected]
* PPP-models for bioeconomy
Type
Players
example
R&D / testing / technological innovation academia & industry, industry‐
industry
BE‐Basic, EBI, CLIB, IAR, TWB, testing / pilot facilities
Market development auctions, cooperatives, market place, (wood) pellets, sugar, agro‐
commodities, flowers, commodity / stock exchanges, vegetables, Etanol (BR)
blending mandates, launching costumer
Infrastructure
industry & government, ngo (ecosystems services), agri‐cultural
Rotterdam port extension, agri‐zoning, land consolidation*
Sustainability criteria
/ certification
industry, ngo, academia, (gov.)
RSB + 100’s others, SCOPE / IPCC / Lorentz BioPanel
Investment/ implementation
(institutional) investors, industry, governments (state‐owned, subsidy), development banks (regional, EIB), Worldbank Group
many (most) 2nd
lignocellulosics plants
multifunctional landscape
(restoration) projects WB
Role of PPP’s while driving the bioeconomy
VTT | Espoo Finland | 02 06 2016
Erick Fernandes (Worldbank), Jan van Breugel (Corbion), Adrie Straathof
(TUD), and Luuk van der Wielen (TUD/BE‐Basic)
http://www.be‐basic.org/downloads
* ruilverkaveling
GHG balance & climate
urgency: scale & scope – actual drivers
•
priorities & options
•
feedstocks – crude oil & biobased
•
feasibility & ‘role’ of advanced biofuels
•
(public-private) open innovation model -examples
land use
change
•
fossil, cement, steel
contents
atmosphere
18.4 bn T/yr
33.4 bn T/yr
land
9.5 bn T/yr
oceans
8.8 bn T/yr
3.4 bn T/yr
Projected sea‐level rise and northern‐hemisphere summer heat events in a 2°C world and a 4°C world
+0.8 o C = +1.4oF
• Increased sea‐level rise from 70 cm to more than a meter
• Increased frequency of extreme and unprecedented heat events
• … and 75% of the poor in dev (agro) countries are hit first
1
Atmospheric CO2 is now higher than it’s been for 650,000 years and increasing rapidly Doubling ‘decades’ : process / agro / logistics are slow industries
in 50 yrs
10000
Doubling in 50 yrs
investment (mio euro’s)
400.26 ppm CO2 level as of February 28, 2015
agro & logistic systems
1000
commercial
100
demo
pilot
10
new product, new application
1
existing product, new application
0,1
0
This graph, based on the comparison of atmospheric samples contained in ice cores and more recent direct measurements, provides evidence that atmospheric CO2 has increased since the Industrial Revolution. (Source: NOAA)
High rate of change
5
10
15
20
25
years
Example: Brazilian ethanol learning curve:
4x cost reduction in 30 yrs /20 x volume increase
vd Wall Bake et al. Biomass & Bioenergy 33, 644-658, 2009
Fossil dynamics: impact on pension funds
1,06
NL pensions funds
Legal minimum 105% (417 bn EUR)
1,04
1.
So we have a time window of a few decades !
1,02
2.
Linked climate and economic impacts
0,98
400 bn EUR
1
-17%
0,96
3.
80% of GHG emissions already locked in existing capital stock
4.
2oC goal: less then 1/3 of proven fossil reserves can be consumed before 0,94
0,92
0,9
0,88
2050 (significant capital and renevue loss**)
0,86
apr-15
5.
70‐95 bn US$ in global annual adaptation costs 6.
Impact investment ‐ required: $ 1…2 trillion in next decade (@10‐30% 350 bn EUR
jul-15
sep-15
okt-15
dec-15
jan-16
mrt-16
mei-16
Total: 150…200 bn EUR capital loss
-24%
profit). 7.
ABP
mei-15
Pension funds : US $ 20 trillion, NL (EUR) 1 trillion
AEX
Scales of biorenewables (illustration)
Tradeble biocommodities - Wood pellet market
*
Demand : stabilisation CO2 emissions of transport
transport fuels = 2 billion ton (GT)/jr worldwide,
annual growth 1.5% or 30 MT/yr (~120 MT/yr biomass)
`
investments in 2nd generation production:
→ 200 plants or $ 50 billion every year
→ every 3 years an extra Port of Rotterdam (360 MT/jr)
→ (or every 5-6 years new Port of Shanghai)
Potential: residuals & energy crops
•
maximum estimate
•
global total demand
•
average
•
double
•
current
50 100
300
450
700
EJ/jr
2
•
•
•
•
SCOPE / UNEP / UNESCO
137 authors from 24 countries of 82
institutes, peer reviewed
BE-Basic 9 of 21 chapters
Launches: Sao Paulo (FAPESP), Nairobi
(UN), W’ton DC (Worldbank), Brussels (EU),
*
contents
•
urgency: scale & scope
•
priorities & options
•
feedstocks – crude oil & biobased
•
feasibility & ‘role’ of advanced biofuels
•
(public-private) open innovation model -examples
Regional priorities: chemical NRW and NL are #1 and # 2 in Europe
… this enables the largest industry cluster
worldwide
sector and transport w/o alternatives (aviation etc)
#1
#2
CO2/ha/yr
… in GHG emissions !
(so we have carbon to be recycled)
mass yield: energy poor (O-rich) in materials*
global production (MT/year)
fuels
2000 (jet 300)
cement 3000 (600 MT CO2)
food
4000 (50% waste)
CO2
glass
120
plastics 280 (big 5: 200)
steel
120 (200 MT CO2)
drop-outs ?
biomass
CH2O0.5
natural gas
C
crude
oil
O
substitutes
Biobased technology is/gets there
“any” chemical can be produced from biobased
feedstocks – by chemo / bio / thermo catalysis
but not all make sense
energy density
increases
cost (benefit)
emission (reduction)
resource efficiency
yield is central parameter
sugars, lactic
ethanol
drop-ins
fuels (energy dense) &
polymers (PE,PP, PS, PVC)
H
mass composition biobased and fossil
feedstocks and products
3
“Drop-in Greenification” of Chemical Industry
B substitute
sustainable ethanol can green EU plastics industry fast
A drop-in
BIOMASS
Biorefinery
Gasification
protein / sugar / lignocellulose
Large scale ethanol-toethylene conversion is
feasible in R’dam.
tomorrow.
Rotterdam
Fermentation and other processes
Aerobic
Fermentation
acetic other
-acid
Iso-butanol
ethanol
Iso-butylene
Ethylene
PETbottles
plastics, Preservatives synthet.
thickeners , plastics polymers
glue
Propylene
Plastics,
surfactants,
detergents
BioPVC
Connected Ethylene Derivatives
18m
Marl
Geleen
Feluy
Tessenderlo
Köln
Jemeppe
BioHydro
carbons
Frankfurt
fertilizer
methanol
Plastics,
carpet
ARG Pipeline
Ludwigshafen
bio-ethylene products
Connected pipelines
=80% chemical industry
From: Ton Runneboom Bio Based Chemicals March
22 2011, Rotterdam
Roadmap for tech innovations in the Chemical and Energy sectors :
“Shell and Cosan Form
$12bn Ethanol Joint Venture
Raizen 21/11/2011
2010
methane SNG
glycerol
Reforming
Paraxylene
Biopower
11m
Oberhausen
Antwerpen
succinic
acid
tons
Connected Ethylene Supply
Terneuzen
An-aerobic
Funct. Lactic
molecules acid
ARG Connections
Energy | liquid biofuels
*
*
2030
2020
System
2nd gen lignocellulosic EtOH
commercial plants
1st gen. EtOH
from sugar cane
2nd gen. advanced
biofuels (hydro carbon-like)
Amyris: “is scheduled to be in
full production of Amyris
1st gen. advanced
renewable products by Q2
liquid biofuels
2012.
(hydro carbon-like)
Abengoa Bioenergy:
“1.3 million gallon/year
capacity demo
plant”.’09
2nd gen lignocellulosic EtOH
pilot and demonstration plants
Sime Darby-Mitsui: “convert
oil palm empty fruit bunches,
or EFB, into bioethanol”.2010
Low-cost lignocellulosic,
thermostable enzymes
Solution
deploy
Process
*
Engineering
POET/DSM 250 M$ = 790 mRM (300 biomass
> 160
ktpa sugars > 100 mio m3 ethanol)
demonstrate
DuPont 235 M$ = 744 mRM (200 ktpa hydrolysate
sugars > 100 mio m3 ethanol)
GranBio 147 M$ = 464 mRM (160 ktpa
sugars > 82 mio m3 ethanol)
ChemTex + Novozymes + DSM
Low-cost lignocellulosic pretreatment
technology for efficient fail-proof intermediate:
low cost sugar (C5/6) platform
*
CO2 + solar light
Develop
(piloting)
Basic Hardware
based (3rd gen) biofuels
DSM-TUD-B-Basic:
“all you can eat
yeast”.2011
C5 & C6 cofermentation ; biomass
N –recycle HTE, -array bioreactors
Genomics & (Directed) evolution
Synthetic biology: novel
pathways, robustness,
rate and yield
Genencor / Novozymes /
photosynthetic micro organisms
DSM: “commercial
to excrete solar biofuels
hydrolytic enzymes”.’10
Low cost photo
bioreactor technology
“the advances made by Joule
Unlimited to achieve direct,
continuous conversion of solar
energy to renewable diesel at 15,000
gallons/acre/year ”2010
Implementing the Bioport Holland PPP concept
Enabling
Technology
discovery
Basic Science
discovery
*
Aviation: GHG-reduction via TOI and jet biofuels
*
NL (bio)Fuelsmix 2050
Aviation 50%
Marine 33%
Road+rail 17%
40000
CO2 emissions (kton/year) in NL at 3% net growth of aviation fuels
consumption
30000
Carbon neutral reference
growth
35000
improved technology, operations, infrastructure
25000
biofuels 1G
biofuels 2G
biofuels tot
aviation
fossil
biofuels
total bio+fossil
reference
20000
15000
proposed path
10000
KLM 1% biofuels in ‘15
5000
fossil fuels
biofuels (1G+2G)
50% GHG emission wrt ‘05
2014
2016
2018
2020
2022
2024
2026
2028
2030
2032
2034
2036
2038
2040
2042
2044
2046
2048
2050
0
International setting is critical for globally operating
industries (transport & chemical)
From “Visie Duurzame Luchtvaart”. SER Report Van der Wielen et al.
June 2014. adopting NL to ATAG ambitions
4
*
contents
Introducing aviation biofuels (NL- numbers)
Fuel-pool composition in
8000
(kton/year)
at 3% net growth of
fuels
consumption
7000
8 (16)
7 mio ton/yr
2G: - 80% GHG
6000
•
urgency: scale & scope
•
priorities & options
•
feedstocks – crude oil & biobased
•
feasibility & ‘role’ of advanced biofuels
•
(public-private) open innovation model -examples
6 (12)
investment
estimates
[bn $]
fossil
4 5000
mio ton/yr
4 Vandaag
(8)
(1G)
4000
3000
doubling jet fuelMorgen (2G)
Biofuels (1G+2G)
towards 90% biojet
2 (4)
150 kton/yr
1G: - 35% GHG
2000
fossil
1000
0.7 mio ton/yr
0
1
2015
3
5
7
9 11 13 15 17 19 21 23 25 27 29 31 33 35
2030
2050
Carbon neutral growth
Platforms from biomass
trends in biobased production
concentration from reactor [kg/m3]
0,01
1
10
10000
1000
flavors &
fragrances
1000
biopharma
Glucose
1000
active ingredients
100
cost price ($/lb)
100
… and most of costs is
(water) separation
100
bio-bulk
10
MAb, HSA
1
10
petrochemicals
1
antibiotics,
nutraceuticals
bioplastics
0,1
0,1
(PLA, PHA, PDO, ...)
Cooney, ‘84
0,01
0,001
waste
[kg/kg]
0,1
Xylose
(2nd gen) biofuels 0,01
1000
100000
10
Plantation image from: biofuel.webgarden.com
production [kT/yr]
Cost contribution of feedstocks
600
feedstocks
biomass
yield
$660/ton
crude oil
0.25
palmitic acid
0.3
Hcomb
105 J/kg
0.34
lignine
glycerol
sugars
biomass
$400/ton
$50..130*/ton
$6/ton
0
Which platforms (redox/mass balance) ?
products
methane
jetfuel/diesel
p‐xylene
ethanol
1,4 BDO
0.5
methanol
1.1
propionic acid
adipic/acrylic
syngas
$1200/ton
ethanol
lignin
ammonia
$400/ton
3
sugars
woodpellets
$402/ton
Only established market: APEX ENDEX Woodpellets ~ $130*/ton
aromatics
butanol
butanol
$800/ton
succinic acid
CO2
jet fuel
crude oils
Hcomb
105 J/kg
lactic acid
citric acid
products
platforms
feedstocks
hydrogen, electricity
butanol
propylene
0.4
1.0
$1600/ton
ethylene
4,5
1,2
syngas
lignin
(p)ethylcarb.
succinic
urea
4,5
1,2,3
ethanol
formic
CO2
(4)
CO2/biochem
30
5
Chemicals price model so far
Oil price vs. sugar price (Europe)
At 100% conversion 100% molar yield
0.80
0.80
London Sugar price (euro/kg)
0.70
0.50
0.40
0.30
0.20
oil
€/kgproduct = €/kgfeedstock  kgfeedstock/kgproduct  1.5
0.60
2010-2011
0.40
2012-2014
Feedstock costs
0.20
Rest
4
3,5
0.00
0.10
sugar
0.00
0.20
0.40
0.60
0.80
Cheaper product when less
conversion steps from oil
Brent oil price (euro/kg)
0.00
Jan‐10
Jan‐11
Jan‐12
Jan‐13
Predicted price ($/kg)
Price (euro/kg)
0.60
Jan‐14
3
2,5
2
1,5
1
0,5
31
32
0
0,0 0,5 1,0 1,5 2,0 2,5 3,0 3,5 4,0
Literature price ($/kg)
Competitiveness compared to ethanol
fermentation
Calculation results
1. Poor: naphtha products (ethene, propene, butenes, BTX)
2.5
2.5
competitive
1,4‐BDO
1,4‐BDO
adipic acid
acrylic acid
acetone)
2
butanone
propylene
phenol
1.5
Relative price (kg basis) Relative price (kg basis) 2. OK: mono alcohols (1-propanol, 2-propanol, butanols,
adipic acid
acrylic acid
2
propylene glycol
ethylene
isobutanol
1‐butanol
isopropanol
1 ethylene glycol
ethanol
0.5
butanone
propylene
1.5
ethylene
1
phenol
isobutanol
1‐butanol
isopropanol
ethanol
3. Good: diols (ethylene glycol, 1,2-propylene glycol, 1,4-
propylene glycol
butanediol)
ethylene glycol
4. Very good: adipic acid, acrylic acid, methyl methacrylate
0.5
not
competitive
0
0
0
0.2
0.4
0.6
0.8
1
Reported fermentation yield of product on glucose (g/g)
0
But is a 1-step conversion by fermentation (or chemocatalysis)
achievable?
0.2
0.4
0.6
0.8
1
Stoichiometrically maximum yield of product on glucose (g/g)
33
contents
34
Biorefinery structure - biomass to integral value
food/feed
•
urgency: scale & scope
•
priorities & options
•
feedstocks – crude oil & biobased
•
feasibility & ‘role’ of advanced biofuels
•
(public-private) open innovation model -examples
harvest /
logistics
pretreatment /
hydrolysis
‘switch’
conversion
to fuels
conversion
to chemicals
nutrients/water
conversion to
power/heat
•
tune portfolio value renewable energy/fuels/chemicals
•
counter-acting scale effects of logistics (5-10% for bagasse,
fuel
chemicals/
materials
renewable
power/heat
30% for palm oil biomass) and conversion costs
•
energy/heat, water, and nutrient integration
•
need for cross-industry sector collab’s (JVs, trade, co-op’s,…)
6
2013: 5 fairly different designs
Winning Team
2013 LST MSc
Design Competition
woodpellets + …  power/heat + ethanol + biochemical + €€ (instead of –SDE)
1,2 PDO
H2O
50
Acrylic
acid
2
EC
O2
240
Ethe
ne
PE
PP
100
2
400
Biosene
Wood
Chips
4000
ktpa
2
H2O
490
H2
60
i-Butanol
50
i-Butene
50
CO
400
H2O
100
2
opt
CO
1,4
BDO
914L
380
H2O
Succini
c acid
CO
100
GTB
E
PX
Methanol
2
MCA
Acetic
acid
i-Butene
Syngas
DMC
39
700
Succini
c acid
Wood
Chips
4000
ktpa
i-Butanol
250
CO
1,4
BDO
Biosene
Acetic
acid
686L
Syngas
H2
30
THF
Ethanol
MCA
100
3HP
Ethe
ne
PE
PP
THF
H2
CO
920
100
PX
SHC
MEG
100
225
Ethanol
2
GTB
E
SHC
3HP
CO
2
1,3 PDO
Lactic
acid
EtOx
100
CO
250
opt
100
100
50
MEG
CO
1,3 PDO
Lactic
acid
H2O
H2O
Acrylic
acid
PLA
EC
100
EtOx
1,2 PDO
PE
C
H2O
PLA
CO
100
DMC
Methanol
40
Authors: Kim Meulenbroeks/
Jan van Breugel
40
REDEFINERY to produce sugars and fuels
500
Coal value
Equal to wood
400
o – transfer price for lignin priced as wood at target NPV
Bunker oil
& Kerosine
o
4 Mt/a
various scales
NPV>0
300
€/t sugars
PE
C
1.5 Mt/a
200
London #5 Sugar Price
(26/06/2015)
NPV<0
100
New York #11 Sugar Price
(03/07/2015)
0
0
200
400
600
€/t lignin
800
NPV= 0 at various scales
wood chips at ‘mid price’ cost of /return on capital at market conform pricing included
Presentation based on public data
7
contents
*
Open innovation model in shells
relevant fields, scout/set options-trends
inspiration vv, HR-PR-reputation <100>
•
relevant academics/fields, scout IP
science foundation, inspiration vv, HR-PR <10>
urgency: scale & scope
conferences
•
priorities & options
•
feedstocks – crude oil & biobased
•
feasibility & ‘role’ of advanced biofuels
•
(public-private) open innovation model -examples
• background knowledge, generate IP
public private HR-PR <4>
• alt.: VC-fund, monitor deal
flow IP private-private <4..10>
‘nice to know’
strategic
access to IP & skills,
JV or B2B partners <1..2>
differentiating, full IP <1>
necessary
core
+
innovation budget + FTE
(incl follow-up)
joint ventures
BE-Basic, other PPS
science foundation, EU, ...
<x> multiplier = (project $ / company $)
budget : risk – impact mapping
About us: www.BE-Basic.org/downloads
*
RD & Innovation strategy
B-Basic &
Ecogenomics
2004-2009
B-Basic
2004-2010
BE-Basic
2010-2015
spin- in via partners
fuzzy
front end
new processes
and products
wild ideas
new companies
lab
R&D
high risk
demo
plant
pilot
plant
full
plant
unbound
unbound
new monitoring
methods
new approaches
(e.g. Smart Soil
for CO2 capture)
failure is
an option
early spin-outs
DISCOVER
DEVELOP
DEMO
DEPLOY
Focus: (1) start-ups , (2) training bio-engineers, (3) pilot facilities
*
Bioprocess Pilot Facility at Delft Biotech Campus N
operational since mid 2012, while being renovated (www.bpf.eu)
80 M€ public-private investment
Bioprocess Pilot Facility at Delft Biotech Campus N
operational since 2012, renovation complete 2014 (www.bpf.eu)
80 M€ public-private investment
8
Synthetic Biology in the real world?
glucose
Successful SME’s in BE-Basic (Q1 2013)
•
TUD-spin-out discovered FDCA-technology for sustainable PET-
xylose
replacement (’09), developed in BE-Basic (’10-’11) for further
arabinose
commercialisation in Corbion (mar’13)
acetate
•
glycerol
WUR-starter pioneer in chemicals from
waste streams, closes series A investment
furanics
with Horizon3 and DGF* (5 apr 2013)
•
DḀB
TUD starter (oct’12) with BPF, TUD, VC
develops advanced biorenewables processes
commercial product
based patent portfolio
… and more to come !
trends in biobased production
The other 70% : FDCA for “BioPEF”
• Top-12 value-added chemicals from biomass
concentration from reactor [kg/m3]
0,01
• Platform chemical - market size 4-12 bn $/yr
• Replace terephthalate in 15 mio ton polymers
• Concept in B-Basic (TUD/TNO - ’09) – FDCA direct
production from lignocellulosic HMF
10
kg-scale process
biomass
cost price ($/lb)
1000
• indust biocat (BIRD Eng /TUD-’09) – bioprocess
(BIRD –’10) – invest round - piloting (BE-Basic-’11)
• 2013 - acquisition of BIRD Eng / FDCA by Purac
1
100
1000
10000
biopharma
active ingredients
100
bio-bulk
10
MAb, HSA
1
petrochemicals
bioplastics
0,1
(PLA, PHA, PDO, ...)
Cooney, ‘84
0,01
0,001
HM-furOH
Bioconstruction materials
(self-healing, cement,
bioconcrete,biogrout,
bioasphalt,, …)
antibiotics,
nutraceuticals
0,1
10
(2nd gen) biofuels
1000
100000
production [kT/yr]
Biogrout & bioconcrete: from soft soil to rock solid
100 micrometer (10-4 m)
In-situ concrete by carbonate fixation
Van Paassen Animations ©
9
conclusions
Combined (drop-in/substitute/-out) scenarios ?
600
products
feedstocks
methane
biomass
yield
$660/ton
crude oil
0.25
palmitic acid
0.3
Hcomb
105 J/kg
0.3
lignine
0.4
0.5
$400/ton
glycerol
sugars
biomass
$50..130/ton
1.0
•
ethylene
industry, far ‘beyond bioethanol’ and
advanced
jetfuel/diesel
fuels
p-xylene
butanol
propylene
ethanol
1,4 BDO
methanol
propionic acid
adipic/acrylic
syngas
lactic acid
succinic acid
connect
2 sectors
w megavolumes
1.1
citric acid
$6/ton
0
CO2
biorenewables can play critical role in chemical & materials
bioconstruction
•
in sustainable (people, planet, profit) development
•
no premiums & subsidies: need to be integral part of
chemicals/ fuels/ food/ energy /logistics system
•
fuels with priority for sectors w/o alternatives
•
public-private partnerships are required to speed-up
development and implementation, in professional setting
55
10
Ecosystems for
business
From incubator spirit to investor interest
By @matthewmarkus (substituting for Richard Yu)
Who am I?
contemporaries
invested in
pembient
Incubator
Richard Yu, Director
Accelerator
Startup
Matthew Markus, CEO
Incubator vs.
accelerator?
Incubator
Accelerator
Selection
Restricted
Via open application
Intake
Continual
Cohorts
Duration
1-5 years
3 months
Model
“Talent pool”
“Pressure cooker”
Mentorship
Limited
Extensive
Focus
Academic
Industrial
Equity stake
None
6-8%
“Demo” day
No
Yes
Focus on IndieBio…
“Biotech has expanded from a drug
based world to now include
everything.”
— J. Craig Venter
Investment themes
●
●
●
●
●
●
●
●
●
Consumer biotech
Post-animal bioeconomy
Future of food
Neuroscience
Medicine 2.0
Regenerative medicine & gene editing
Microbiome
Exobiology
Immunology Sampling of the
portfolio…
Pembient
Animals are Precious
Traditions are Important
Rhino Horn
Wild
Biofabricated
???
$12k/kg
Wild Horn
$8k/kg
Reseller
+192%
+338%
$35k/kg
Asymmetric Information
Buyer
Biofabricated Horn
Resellers
$35k/kg
$35k/kg
$35k/kg
???
EV = $8,750/kg
Adverse Selection
Buyer
$35k/kg
1.
Markup on cost of biofabricated horn entices resellers.
2.
Probability of buying a biofabricated horn increases.
3.
Expected value of any given horn decreases.
4.
Market equilibrium resets.
5.
The cost of biofabricating horn decreases.
— based on —
The Market for Lemons
Quality Uncertainty and the Market Mechanism
by George Akerlof, Ph.D.
Published: 1970
Nobel Prize: 2001
“What’s past is prologue.”
— William Shakespeare
●
●
●
●
●
Since 5/2015
$50k for 8%
$25k CLN
10 startups/year
BSL-2 lab
●
●
●
●
●
Since 2/2015
$50k for 8%
$150k CLN
30 startups/year
BSL-1 & BSL-2 lab
IndieBio
EU
founded
●
●
●
●
●
Since 1993
Cork, Ireland
$250m AUM
6 accelerators
Global
rebranded
●
●
●
●
●
Since 5/2014
Cork, Ireland
$30k in funding
Bench space
Mentorship
IndieBio
SF
Who is IndieBio SF?
Arvind Gupta
Managing Partner
Ryan Bethencourt
Program Director
Involved with Berkeley Biolabs & Counter Culture Labs
Ron Shigeta
Scientific Officer
Involved with BioCurious & Berkeley BioLabs
“Geography is destiny.”
— Napoleon Bonaparte
(attributed)
“The Edge… there is no honest way to
explain it because the only people
who really know where it is are the
ones who have gone over.”
— Hunter S. Thompson
Metrics of success
●
93+ mentors, including:
○
○
○
●
42+ companies, including:
○
○
○
●
George Church, Professor, Harvard Medical School
Isha Datar, President & CEO, New Harvest
Linda Avey, Founder, 23andMe
Clara Foods with $1.7m seed round
Memphis Meats with $2.75m seed round
NERD Skincare with $1m seed round
Publicity:
○
○
4000+ Twitter followers
TechCrunch, Fast Company, Forbes
How can the Finnish investors respond
to enable growth in the field?
Financing opportunities for Finnish growth companies
Industrial Biotechnology Business Seminar
Eeva Grannenfelt
2.6.2016
Grannenfelt Finance Ltd
 Grannenfelt Finance is an independent family-owned provider of
financial solutions for SMEs and growth companies, established in
2015
 Our goal is to find comprehensive funding solutions for SMEs and
growth companies that support growth during the entire life cycle
of the company – thus enabling businesses to focus on growth
without a constant worry about the funding
 Today’s funding opportunities are diversified and fragmented
outside the conventional banking sector to private, government
and EU solutions
 We combine the suitable funding options effectively to our
customer’s individual needs
Society Should Create Opportunities and
Remove Obstacles
Wide-ranging funding solutions
Banks
Insurance Companies
Pension Funds
Venture Capital
International investors,
private equity and loan
funds
Private Equity Funds
Loan Funds
Family Offices
Stock Markets
Business Angels
ARMADA
Government/EU funding
Crowdfunding
Life cycle financing
•
•
•
•
•
•
•
•
Tekes
Ely-center
Finnvera
Angels
Seed-funds
Venture funds
Crowdfunding
Banks
*Valley of death 1.
Start-up
•
•
•
•
•
•
Finnvera
EIB
Banks
Pension and
insurance funds
Venture funds
Loan funds
•
•
•
•
EIB
Banks
Buyout-funds
Late stage venture
funds
***Valley of death 3.
**Valley of death 2.
Internationalization
* First valley of death appears in ** Second valley of death
the early stage of company life appears when company is
cycle
entering to the global markets
•
•
•
•
IPO
Banks
EIB
Capital markets
Growth
*** Third valley of death appears
while problems arise from global
leadership and from cultural
differences
Stability
http://techcrunch.com/2015/11/11/nokiasfall-means-the-rise-of-startups-in-finland/
The most exciting
startup scene you have
never heard of isn't in
Seattle, or London—it's
in Scandinavia.
"There's been a rise of startup
communities in Finland and other
Nordics as well. These communities
function at the intersection of
municipality, corporations and
academia, bridging gaps and opening
up exciting opportunities for their
startups," said Panu Keski-Pukkila,
founder of Hardware Startup Finland.
http://www.slate.com/blogs/moneybox/2015/12/18/the_n
ordic_startup_scene_is_second_only_to_silicon_valley.html
Grannenfelt Finance
Fredrikinkatu 35 B 11
00120, Helsinki
www.grannenfeltfinance.fi
Eeva Grannenfelt
Lasse Grannenfelt
+358 50 544 6355
[email protected]
+358 40 717 8572
[email protected]
Rational design of microbes for competitive
biotechnological processes
Isabel Rocha, CSO
[email protected]
2016-06-02
www.silicolife.com
in silico design of
optimal cell factories
- Founded in 2010 and privately owned by its founders
- Enabling the design of optimized microbial strains for the production of
biofuels, chemicals or biopolymers
- Player in the design step of the synthetic biology cycle, using models,
simulation and optimization
- Bridging computer sciences, life sciences and bioengineering
- Working with leading chemical, materials and synthetic biology
2
companies
Industrial Biotechnology
3
Improve the economics of the processes
- Productivity:
- Yield:
- Specificity:
investment costs
raw material consumption
investment and operational costs
Improve the microbe
4
Improving the microbe
To produce desired products it is generally necessary to retrofit the
metabolism. Where to start???.....
Raw material
Product
By-products
5
5
The GPS analogy…
?
?
?
?
?
GPS
?
Carbon
Source
6
Desired
Product
6
A complete pipeline from the
problem to the solution
Problem from client
Development Partners
?
Strain optimization
for desired end
product
Using computational biology
to tailor metabolic pathways
Network of partners:
 Wet lab
 Genome sequencing
 State-of-the-art
from Academia
7
Synthetic biology recombining nature
diversity
 In silico screening of genes from
heterologous organisms
 Evaluation of yield opportunities for
reaction alternatives
 Selecting the most efficient
heterologous genes
8
Designing new synthetic pathways
?
1. Characterize the transformation
?
?
2. Identify enzymes performing similar transformations
3. Enumerate putative enzymatic options from source to target
 Discovery of new activities and pathways
 Exploration of promiscuous enzymatic activities
 Evaluation of the use of alternative substrates with similar
functional groups
 Enumeration of alternative pathways and intermediates
9
Working with leading chemical, materials and
synthetic biology companies
Contracted projects with:
 Fortune 500 companies
 Multinational conglomerates
 World leading agri-business companies
 Global leaders in building block chemicals,
polymers and biosynthetic development
10
Collaborating in R&D projects
Selected national and european projects:
• H2020 – DD-DeCaF – Bioinformatics tools for
industrial biotechnology
• FP7-KBBE: BRIGIT, Biotechnology for novel
biopolymers, 2012.
• ERA-IB-2: DeYeastLibrary, Designer yeast strain
library optimized for metabolic engineering, 2014.
• ERA-IB-2: ICPRES, Integrated Process and Cell
Refactoring Systems for Enhanced Industrial
Biotechnology, 2014.
• ERA-IB-2: DYNAMICS, Analysis and optimization of
industrial microorganisms under dynamic process
conditions, 2015.
11
A multidisciplinary team
which includes expertise in the Life Sciences,
Bioengineering, Computer Science and
Bioinformatics with > 15 people.
Executive team
Simão Soares
Isabel Rocha
Chief Executive Officer
Chief Scientific Officer
MSc Bioinformatics
BSc Informatics Engineering
Board member P-Bio
PhD Chemical Engineering
UMinho Faculty
Founder Biotempo
Miguel Rocha
Paulo Vilaça
Chief Technology Officer
Chief Operations Officer
PhD Computer Science
UMinho Faculty
Bioinformatics expert
MSc Bioinformatics
BSc Informatics Engineering
Bruno Sommer Ferreira
Chief Business Development Officer
PhD Biotechnology
Biotrend CEO
12
Designing the new generation of bio-based
products
Address
SilicoLife Lda.
Rua do Canastreiro, 15
4715-387 Braga
PORTUGAL
Phone
+351 253 540 107
E-mail
[email protected]
Isabel Rocha, CSO
[email protected]
www.silicolife.com
OptFlux: a metabolic engineering
open-source show-case
More info
www.optflux.org
OptFlux: an open-source software platform for
in silico metabolic engineering.
BMC Systems Biology 4:45, 2010.
14
@note2: a biomedical text-mining platform
 Publication management
 Information retrieval and
extraction
 User-friendly
 Plug-in based and opensource
More info www.anote-project.org
15
HIGHLY EFFECTIVE ENZYME
SOLUTIONS FOR CELLULOSIC
BIOMASS CONVERSION
METGEN AT A GLANCE
•
MetGen develops and markets enzyme solutions into growing biomass
markets within the energy, pulp and paper, packaging, polymers and plastics
sectors
•
The majority of biomass conversion processes have low yields, consume
large amounts of energy or chemicals and are highly capital intensive
•
Enzymes are the preferred and most sustainable solution to convert
cellulosic biomass into valuable fibers, renewable fuels and chemical
building blocks
•
MetGen’s industrial enzymes enable cellulosic biomass conversion at high
yields and low cost
•
The unique MetGen enzymes are tailored to withstand harsh industrial
environments (extreme pH, high temperatures, presence of inhibitors)
•
The enzymatic performance has been validated in multiple industrial trials
•
The fermentation process allows competitive enzyme production cost
OUR MISSION
EMPOWERING INDUSTRIES TO
ENHANCE VALUE OF BIOMASS
USING ENZYMATIC SOLUTIONS
ENZINE® TECHNOLOGY PLATFORM
•
•
•
•
FAST: Industry leading short
development cycle
Technical
support
FLEXIBLE: Tailored enzyme
design approach to meet
challenging industrial conditions
ADAPTABLE: Can produce large
amounts of different enzymes,
cost-effectively
PROVEN: Developed three novel
enzymes from concept to
validation at industrial scale and
production
Industrial
supply of
enzyme
Identified
Customer
Challenge
Unique
Combination
Piloting and
scale-up
Application
testing
Designing,
cloning
and
screening
UNIQUENESS OF ENZINE® PLATFORM
•
•
•
•
•
Dedicated Technical
Support
Industrial scale enzyme
production
Cost-effective, efficient
process
Pilot fermentation facility
with downstream
processing
Fast-track to industrial
production including
optimized strain and
production protocol
Technical
support
Industrial
supply of
enzyme
Identified
Customer
Challenge
Unique
Combination
Piloting and
scale-up
Application
testing
Designing,
cloning
and
screening
•
•
•
•
•
•
Continuous IP
landscaping
Unique genetic
engineering capabilities
Extensive libraries of
highly potent clones
In-depth knowledge of
client requirements and
applications
Special testing equipment
Protocols for industrial
scale testing
MANAGEMENT TEAM
Alex Michine
Klara Birikh
Matti Heikkilä
CEO
R&D Director
CTO
Sami-Pekka Rantanen
Toni Grönroos
Antoine Mialon
Sales Director
Solution Development Manager
Application Team Leader
METGEN INDUSTRIAL ENZYME SOLUTIONS
Pulp and Packaging
•
•
•
•
Energy and cost savings
Product quality improvements
Process improvements
Sustainability improvements
Biorefineries
•
•
•
•
Lowering overall enzyme costs
Higher sugar yields
Less CAPEX through more
compact processes
Novel biochemicals from
lignocellulosic sugars
Product
BRILATM
FORICOTM
SEKALOTM
POVONTM
Application
MECHANICAL
PULPING
TISSUE
EFFLUENT
CONTROL
PAPER
COATING
FLUTING
LINER
WOOD CHIPS
REJECT PULP
DEINKED PULP
RCF
EFFLUENT
STARCH
CHEMICAL PULP
NSSC
Efficiency and
Energy Saving
Quality & Process
Improvements
Energy & Raw
Material Savings
Peroxide Removal
Improved
Biogas
production&
Water treatment
Economic
Starch
Conversion
Quality & Process
Improvements
Energy & Raw
Material Savings
Benefits
LIGNOTM
Enzyme
Added to
METZYME® PRODUCT FAMILIES
FOR PULP AND PACKAGING
METGEN STRATEGIC FOCUS:
Lignocellulosic biomass conversion in multiple segments
PULP AND PAPER
VOLUME OF
LIGNOCELLULOSIC
RENEWABLE
CHEMICALS
BIOFUELS
BIOMATERIALS
MetGen process cellulosic biomass into pulp/fibers or cellulosic sugar.
Value-added products are made of these intermediates
Packaging,
Tissue,
Paper
Biobased
plastics
Energy and
liquid fuels
Nano
cellulose
METGEN GO-TO MARKET PLAN
STRENGTH
INCREASE
ENERGY
SAVING
BIO
REFINERY
EU Rollout
Americas
First EU sales
Pilot trials
2016
Industrial
trials
Global
EU Rollout
N.America
Global
Global Sales
2017
2018
MetGen’s current markets for enzymes are
• Fiber Strength increase and process improvements in tissue and packaging
board production
• Energy Saving In wood pulping processes
• Cellulosic biomass hydrolysis and sugar conversion in biorefineries
• Cellulosic sugar isomerization for renewable plastics
RECYCLED FIBRE & DEINKED PULP
STRENGTH IMPROVEMENT
MetZyme ® BRILATM
dosed on RCF or
Virgin fibre
Tissue or Board
machine
Challenge
Unplanned downtime machine costs around €1 Mln p.a
Solution
MetZyme® BRILA™ improves product properties
Results
Product breakage decrease up to 60% and downtime
reduced by 50%
Value Proposition
Net Savings to Mill € 0.5 Mln p.a
Reference
Industrial Mill trials
CHEMICAL PULP / NSSC
STRENGTH IMPROVEMENT
MetZyme ®
POVON TM dosed on
NSSC
Fluting paper
machine
Challenge
Paper machine runability issues
Unplanned downtime machine costs around €1 Mln p.a
Solution
MetZyme® POVON™ improves strength properties
Results
Paper machine web-breaks decreased up to 60%
Value Proposition
Net Savings to Mill € 1 Mln p.a
Reference
Industrial Mill trials at >300 000 tons p.a
PULP PROCESSING - ENERGY SAVING
Wood chips
treated with
MetZyme ® LIGNOTM
Pulp production in
refiners
Challenge
Average mill spends €20 million/year on energy, refining is
50% of the electricity bill
Solution
Reduce energy consumption by treating wood chips with
MetZyme® LIGNOTM
Results
20% less electricity consumption and final product strength
increased 10-15 %
Value Proposition
Net Savings to Mill operator €1.5 Mln p.a
Reference
Industrial Mill trials
PEROXIDE REMOVAL FROM EFFLUENT FLOW
MetZyme®
FORICO TM added to
reactors
Effluent treatment
facility
Challenge
Wastewater, normally used in biogas production, can’t be used if
contaminated with residual peroxide
Solution
MetZyme® FORICO™ deactivates residual hydrogen peroxide
when applied to aerobic effluent reactor
Results
Residual hydrogen peroxide fully degrades in under 1 hour
Value Proposition
Case by case
Reference
On going commercial supply to paper mill
STARCH CONVERSION FOR PAPER COATING
MetZyme® SEKALO TM
added to pure starch
Paper machine
Challenge
The high cost of starch modification
Solution
Substitute chemicals for MetZyme® SEKALO™ to lower cost
Results
Same surface strength, lower costs
Value Proposition
Mill saves €400,000/year on average
Reference
Mill Trials
BIOREFINERIES - CELLULOSIC SUGARS
MetZyme ®
SUNOTM added to
pretreated biomass
Conversion to
sugars
Challenge
High enzyme cost with challenging lignocellulosic biomass
Inhibition at high consistency of biomass
High capital and operating cost
Solution
MetZyme® SUNO™ Tailor-made Drop-in solution
Results
Sugar yield increase 20% or enzyme dosing decrease of 50%
Biomass consistency >20%
More compact processes and lower CAPEX
Value Proposition
15% savings in sugar production cost
Reference
Pilot scale & H2020 Projects BIOrescue and ButaNexT
BIOREFINERIES – RENEWABLE PLASTICS
MetZyme ®
PURECOTM
glucose isomerase
added to
hydrolysate
Conversion to
sugars
Challenge
High enzyme cost with challenging lignocellulosic biomass
Commercial enzymes are inhibited by biomass
Solution
MetZyme® PURECO™ Glucose Isomerase
Results
Isomerization in non-purified hydrolysates
Better stability, yield increase and total productivity increase
More compact processes and lower CAPEX & OPEX
Value Proposition
Enabling technology for lignocellulosic plastics
Reference
Lab scale
H2020 projects ReTAPP and BIOFOREVER
LONG TERM OPPORTUNITIES
MetGen aims to drive profitable growth in global markets

New and sustainable bio-based materials

Renewable alternative to petrochemicals

Clean & safe environment
PULP & PAPER
ENZYME COCKTAILS
NANO
CELLULOSE
BOARD
STRENGTH
TISSUE
ENZYMES
RENEWABLE CHEMICALS
Technical
Industrial
support
XYLOSE
supply of
ISOMERASE
enzyme
XYLOSE AND
FURFURAL
XYLOSE
REDUCTASE
XYLITOL
Desing,
cloning
and screening
WASTEWATER
TREATMENT
OXIDOREDUCTASES
PHENOLS REMOVAL
MetGen is helping the bio-based industries materialize their full potential
ENZYMES FOR BIOREFINERIES. WHAT’S NEXT?
Ready for optimization
Nanocellulose
Candidate enzymes for
development
(MetZyme®PURECO™)
MetZyme
® LIGNO™
Aldose
reductase
Sorbitol
Value-added products
Cellulose
C6 (Glucose)
Fructose
HMF
MetZyme®
PURECO™
MetZyme®
LIGNO™
MetZyme®
SUNO™
L-Xylulose
D-Xylose
reductase
BIO
MASS
Hemicellulose
Xylanase,
Xylosidase
C5 (D-Xylose)
Xylitol
Xylitol-4dehydrogenase
Xylosidase
Acetyl xylan
Esterase
D-Xylulose
MetZyme®
PURECO™
Lignin
Xylose
isomerase
Furfural
Chemical
derivates of
Lignin
Opportunity in MDF Board strength improvement
MetZyme® LIGNO™
added to wood mass
Plywood
Hot-pressing
Challenge
Increasing MDF board strenght
Solution
Treating fibers with MetZyme® LIGNO™ may increase of internal
bond strength
Results
Need to be verified in relevant scale
Value Proposition
30– 50 % internal bond strength
Reference
Scientific articles
WASTE WATER APPLICATIONS
MetGen laccases
added to waste water
Normal waste water
treatment with
decreased COD,
phenols and other
micropollutants
Challenge
“Hard COD”, phenolic compounds and other micropollutants
Solution
MetGen laccases reduce COD and micropollutants
Results
Reduction of 40% of COD and phenols from pulp and paper mill
waste water. Significant reduction of various micro pollutants using
synthetic solutions (e.g. >95% reduction of Bisphenol-A)
Value Proposition
Further technical solutions required before commecial application.
Legistlation does not require redution of micro pollutants at this
time. MetGen provides ability to foresee the change in regulation.
Reference
Laboratory trials using industry waste water (COD & phenols) and
synthetic solutions (micropollutants)
REDUCING MICROPOLLUTANTS FROM WASTE
WATER
MetGen’s laccases have been tested in laboratory on synthetic
micropollutant solutions.
In these
test to
significant reduction of various
laccases
added
micropollutants was demonstrated
waste water in laboratory scale.
Diclofenac
Estradiol
Estrone
Ethynilestradiol
Triclosan
Bisphenol-A
Nonylphenol
Carbamazepine
Naxopren
Anthracene
Benzo(a)pyrene
Phenanthrene
Pyrene
WASTE WATER APPLICATION STATUS
• MetGen began testing the
molecules on industrial waste
water already in 2005.
• Due to the lack of enforced
legistlation there was no interest
to reduce the micro pollutants in
waste waters
• MetGen has IP on the enzymes
• MetGen has on-shelf enzymes
designed for harsh conditions
• MetGen has the capability to
produce the required enzymes in
industrial scale.
• MetGen is interested to
collaborate on developing
technical solutions for a
commercial application in waste
water treatment:
– ”Single-use” enzyme may not
be the most affordable solution
for waste water treatment
– Commercial application may
require immobilization of the
enzymes to be used more than
once for improved economics
WHY METGEN?
•
Repeat demonstration of outstanding enzyme performance in harsh
industrial environments
•
Customer adopted enzymatic solutions that address customer needs
•
Industry leading short development cycles for new enzymatic solutions
•
Versatile plug&play enzyme expression platform
•
Multiple market ready enzymatic solutions tested at industrial scale
•
Commercial production capabilities using qualified European contract
manufacturers
•
Lean business model with low breakeven point
LASTING SOLUTIONS FOR CUSTOMER
ARE ALWAYS BUILT THROUGH COLLABORATION
R&D Team
Technical Team
Business Team
Identification and
development of
MetZyme® solution
addressing these
challenges.
Together with mill team,
identification of optimal
place in process to apply
MetZyme®
Commercialization of
product
Sales Contact
Process challenges
are discovered while
meeting with mill
personals
Application
Testing Team
Technical
Team
Technical
Support Team
Reporting on test
results MetGen has
achieved with
customer specific
material (pulp,
biomass, process
water) using selected
MetZyme® prototypes.
Further optimization
of specific product
and application for
customer
Continuous technical
support for product
implementation and
better results
FUNDING PARTNERS &
COLLABORATORS
Equity investors
HST Partners Oy
Collaborators
Goverment
VISIT
METGEN.COM
[email protected]
Enabling the use of CO2 as an
industrial fermentation feedstock
EnobraQ Confidential
1
What if CO2 was part of the
solution …
…and not only an issue?
EnobraQ Confidential
2
What if we could produce competitive
and yet sustainable chemicals?
What if you could buy sustainable and
yet competitive chemicals?
EnobraQ Confidential
3
From academic research to start up development
2011
2012
2013
TWB
inception
2014
2015
2016
2017
Carboyeast
extension
Carboyeast period
Carboyeast
project
started
EnobraQ
inception
Fully
operational
Series A
EnobraQ period
SGSF 1st
tranche
investment
EnobraQ Confidential
2nd tranche
investment
4
EnobraQ tries to reverse what has been attempted
What people usually do:
Trying to domesticate new
microorganisms that already have
photosynthetic/"gas-trophic"
capabilities but that no one knows
how to use it industrially
What we do :
Develop autotrophic capabilities on
well known industrial fermentation
"existing working horse" like yeasts
Slow and painful metabolic
engineering development
Most of the technical risks are upfront
(initial metabolic engineering)
Scale up and industrial uses of these
organisms is a complete "terra
incognita" with very high profile risk
Scale up and industrial uses of yeasts
are very well known and is somehow
predictible
EnobraQ Confidential
5
Technology concept
Three simple concepts :
1. Modify a yeast in order to enable it to use CO2 as a plant
2. Use hydrogen as a convenient source of energy (instead of light)
3. Use it to produce valuable chemicals leveraging on existing pathways
Cheap feedstock
compared to
other sources of
carbons
Dark reactions
involving
RubisCo
CO2
yeast
chemicals
H2
Efficient and
practical source
of energy and
atoms
Energy through
hydrogenases
Industrially
proven
organism ready
to be modified
EnobraQ Confidential
Wide portfolio of
possible products by
genetic engineering
6
Compare to sugar, our feedstock is much cheaper
Sugar price for the last 30 years and sugar cost equivalent to EnobraQ feedstock cost
Worst case today
Average case today
Best case today
Projection in the
future
EnobraQ will provide a dramatically lower feedstock cost that :
• increases margins on existing commodity markets
• unlocks very large new drop in markets
EnobraQ Confidential
7
Complementary skills with a lean management
An R&D outsourced model similar to pharma startups
Cedric Boisart
CTO
Michael Krel
CEO
• 6 years leading business
development efforts in two French
IB ventures
• 3 years of VC activity in IB and
renewable chemistry
• Former consultant with a PhD in
organic chemistry
• 15 years of experience in industrial
biotech
• Former Strategic Development Manager
with Soufflet Biotechnologies
• Former CTO of Carbios, leading the
partnership with TWB
• Led the bioinformatics team of
Metabolic Explorer
Leveraging expertise from TWB (more than 250 biotech
scientists and engineers) with a 15FTE team
EnobraQ Confidential
8
A full skillset around the table
Board members
Denis Lucquin
Managing Partner
@Sofinnova
Leopold
Demiddeleer,
chairman
Former head of New Business
development with Solvay
Nathalie Turc
Observer
Deputy director of
Institut Carnot 3BCAR
Scientific advisors
Denis Pompon
Philippe Soucaille
Stephane Guillouet
lead scientist on
hydrocortisone project
industrialized by Sanofi
Lead scientist on 1,3
PDO project
industrialized by DuPont
lead scientist on
European
Alphabird project
Top academic skills with strong collaborative industrial experience
EnobraQ Confidential
9
EnobraQ highlights
• Patented breakthrough science from top tier academic teams
based in France
• Process leading to shut down economics in several commodity
industries
• Lean and experienced management leveraging TWB labs
• May attract investments and interests outside classical IB
players because of CO2 utilization
• Strong leverage of public financing
EnobraQ Confidential
10
Enabling the use of CO2 as an
industrial fermentation feedstock
[email protected]
Confidential
+33EnobraQ
(0)6 31
21 31 86
11
Living Factories
Industrial biotechnology in Finland - the path forward
Tanja Dowe, Innomedica Ltd
03/06/2016
Living Factories
Creating Bioeconomic Growth–
Industrial Biotechnology Business Seminar
Espoo, Finland 2.6.20161
Living Factories
Synthetic Biology in Finnish bioeconomy
03/06/2016
2
Living Factories
Same old biotechnology... or not?
2016
2003
The human genome project completed:
13 years
USD 2.7 billion
An individual’s or production organism’s
genome sequenced:
3 days
USD 1000
...
...
...
Illumina Hi-Seq X Ten
Synthetic
Biology
1800 disease genes
350 products in clinical trials
CRISPR
2000 genetic tests
CHASSIS ORGANISMS
BIOIT
03/06/2016
3
Living Factories
The potential of synthetic biology in bioeconomy
New conversion
pathways & production
organisms
Existing bioeconomy raw materials
Plant oils
Sugars
Microbial oils
03/06/2016
Existing products
Biofuels
Chemicals
Materials
4
Living Factories
The potential of synthetic biology in bioeconomy
New bioeconomy raw materials
CO2
Methanol
H2
Waste
New conversion
pathways & production
organisms
Existing bioeconomy raw materials
Plant oils
Sugars
Microbial oils
03/06/2016
Existing products
Biofuels
Chemicals
Materials
5
Living Factories
The potential of synthetic biology in bioeconomy
New bioeconomy raw materials
CO2
Methanol
New products
Chemicals
H2
Waste
Polymers
Biosynthetic
materials
New conversion
pathways & production
organisms
Existing bioeconomy raw materials
Plant oils
Sugars
Microbial oils
03/06/2016
Existing products
Biofuels
Chemicals
Materials
6
Living Factories
The potential of synthetic biology in bioeconomy
New bioeconomy raw materials
CO2
Methanol
H2
New products
Synbio:
Chemicals
Waste
DNA sequencing
DNA synthesis
Bioinformatics
Biosynthetic
materials
Biologic
components
Existing bioeconomy raw materials
Plant oils
Sugars
Microbial oils
03/06/2016
Polymers
New conversion
pathways & production
organisms
Sustainability
Cost-efficiency
Integrated
systems
Pharmaceuticals
Energy
Chemicals
Existing products
Biofuels
Chemicals
Materials
7
Living Factories
The potential of synthetic biology in bioeconomy
New bioeconomy raw materials
CO2
Methanol
H2
New products
Synbio:
Chemicals
Waste
DNA sequencing
DNA synthesis
Bioinformatics
Biosynthetic
materials
Biologic
components
Existing bioeconomy raw materials
Plant oils
Sugars
Microbial oils
Raw material owners
New conversion
pathways & production
organisms
Sustainability
BioIT comps
Synbio tech start-ups
Investors
Pharmaceuticals
Energy
Chemicals
Integrated
systems
Existing products
Biofuels
Chemicals
Materials
Cost-efficiency
Universities and
research centers
03/06/2016
Polymers
CROs
End-product companies
Infrastructure providers
8
Living Factories
Ecosystems and initiatives
Biosustainability
Center
IBC Finland/ LiF
CLIB
Toulouse White
Biotechnology BEBasic
ERASynBio
CSynBio
acib strategic vision
UK 60 M£ EU ERASynBio
DOE 10 MUSD
17 MEUR
SynBERC
Synthetic Biology
NSF 70 MUSD
CHINA 30
Roadmap for the UK
MUSD
USA National
Opprotunities for
Bioeconomy Blueprint
Scotland in synthetic
biology
iGem
03/06/2016
9
Map: galleryhip.com
Living Factories
Finland?
 We need spearheads for economic growth
 We have a legacy of industrial biotechnology
 We need to collaborate
03/06/2016
10
Living Factories
Roadmap
Vision
With synthetic Biology towards sustainable bioeconomy
Majority of industrial production based on biotechnology
Four strategic themes
Protein
products
and production
technologies
Bio-IT
Chemicals and fuels
Biosynthetic
materials
03/06/2016
11
Living Factories
Synbio-PPP
Powerhouse
Enablers
Mapping of IPR &
commercial potential
Computer-aided
designs of enzymes
Synthetic
production
organisms
Products and
applications
Production
concepts
03/06/2016
Genome
editing tools
Useful products from
organic wastestreams
Wider variety of
enzymatic
reactions
Production organisms
designed with
mathematical cell models
Bioethanol with
modified yeast
Synthetic production
organisms reduce number
of unit operations
Now
All industrial
sidestreams exploited
Cost-efficient utilization
of single carbon (C1)
raw materials
Biotechnical
valorization of
Lignin
Higher yield
enzymes
General attitude
and approval
Wide industrial
use of enzymes
and on-demand
enzyme synthesis
Synthetic enzymes
that utilize C1
Synthetic
yeast
Cell switches for
synthesis timing
Fotosynthesis
efficiency
improved
remarkably
From virtual models
to automated cell &
molecular synthesis
New bio composites
Materials and
made with synthetic cell parts for 3D printing
cells
Living
Animal
Smart materials
materials
Aromates produced proteins from
based on biological
Biohydrogen
biotechnically
microbes
functionality
Non-oil base
chemicals in
production
Pharma molecules
with synthetic
Biogames
enzymes
Science based
entrepreneurism
Open
Enabling
innovation
regulation
Therapeutic
human proteins
from microbes
Cell level
modeling in
process design
Mid-term
Novel type of
economical process
enabled by synbio
New solutions for
storing energy
Biotechnology used
widely accross indistry
sectors
Long term
12
VISION
With synthetic Biology towards sustainable bioeconomy
Majority of industrial production based on biotechnology
Tailored
enzymes
Networked
company
Synbio-infrastructure ecosystem
from lab to pilot
High value
products from
biomass sugars
Raw materials
”BioSlush”
Living Factories
We need a common will
1. To develop production pathways for higher value products, e.g. more valuable
composites and biochemicals based on the needs of companies marketing the
end-products.
2. To develop synthetic biology technologies that enable the production of new
products, the utilization of a larger variety of raw materials, and large and
small scale production. Research institutes, universities and public financiers
must guarantee the continuation of high-quality synthetic biology applied
research in Finland.
3. To establish a PPP working group, Synbio Powerhouse.
03/06/2016
13
Living Factories
Synbio Powerhouse
Industry
Academia
Investors
IBC
Start-ups
Other stakeholders
 Mission: to coordinate the industry-academia collaboration, the
development of the synbio start-up culture and the providing of
expert advise and consultation to different stakeholders.
03/06/2016
14
Living Factories
The real breakthroughs of synthetic
biology will be made in the industry, not in
research.
- Greg Venter
03/06/2016
15
Living Factories
03/06/2016
16
1
12.4.2016
Esa Aittomäki
Megatrends and drivers
Value chain creation
Role of synthetic biology
2
Esa Aittomäki
2.6.2016
Megatrends in biobased industry development
 CO2 emissions, global warming → governmental mandates
 Independence from fossil raw material, use of renewable sources
 Sustainability: reduction of carbon and water foot print, step out from
food chain, looking for biobased products and biodegradable plastics
 Brand owners’ image: Coca Cola, Danone, IKEA, LEGO, L'Oréal,…
3
Esa Aittomäki
2.6.2016
Drivers to biobased industry
4
Esa Aittomäki
2.6.2016
Drivers to biobased industry
Producers,
developers
Technology
developers
End users,
brand owners
5
Esa Aittomäki
2.6.2016
Value creation
Grass
Intermediates
Biogas
Products
Energy
Ethanol, butanol
Fuels
Triglycerides
Grain
Amino acids
Biochemical
Pulp
SCP
Food, feed
Acids
Surface active c.
Diacids
Pharma, cosmetics
Cane
Fractionation
Oil seeds
Thermochemical
Sorbitol, xylitol
Lignocellulose
fractionation
Straw
Lubricants
Modified starch
Solvents
FDCA
Chemicals
3-HPA
Forest
PDO, BDO
Emulsifiers
Thermal (pyrolysis)
3-HBL
Glycerol
Pulp mills
Biopolymers
Resins, glues
Furfural
Gasification/combustion
Modified polymers
Lignin
Waxes
6
Esa Aittomäki
2.6.2016
BTX chemicals
Biorefinery value chain development –
biotechnology as an enabler
Primary raw
material
Conversion
step 1
Primary
intermediate
Conversion
step 2
Intermediate
Final product
Formulation
Semi final
product
Conversion
step 3
BC
7
Biochemical route
Esa Aittomäki
C
Chemical route
2.6.2016
What’s going on in biobased chemicals
IEA 2010
Succinic acid
DOE 2015 TOP 12
BC
DOE 2016 Near term chemicals
1,4-diacids (succinic, fumaric, malic)
BC
Butadiene (1,3-)
BC
C
Butanediol (1,4-)
BC
Ethyl lactate
BC
BC
Furanics
C
FDCA (2,5-furan dicarboxylic acid)
Hydroxypropionic acid/aldehyde
BC
3-HPA (3-hydroxypropionic acid)
Glycerol derivatives
C
Levulinic acid
C
Fatty alcohols
Sorbitol
C
Glycerol
C
Furfural
C
Xylitol
C
Glucaric acid
BC
Glycerin
C
Levulinic acid
C
Aspartic acid
BC
Isoprene
BC
BC
Lactic acid
BC
C
Propanediol (1,3-)
BC
C
Propylene glycol
Biohydrocarbons
BC
3-hydroxybutyrolactone
Lactic acid
BC
Sorbitol
Ethanol
BC
Xylitol
BC
BC
BC
Glutamic acid
BC
Succinic acid
Itaconic acid
BC
Xylene
BC
Biochemical route
C
Chemical route
http://www.nrel.gov/docs/fy16osti/65509.pdf
http://www.ieabioenergy.com/wp-content/uploads/2013/10/Task-42-Biobased-Chemicals-value-added-products-frombiorefineries.pdf
http://www.biofuelsdigest.com/bdigest/2015/04/30/the-does-12-top-biobased-molecules-what-became-of-them/
8
Esa Aittomäki
2.6.2016
C
BC
C
Techno economic hurdles
 Poor feasibility of process concept, value of products and by-products;
need to valorize side-streams
 Availability of raw material and price
 Technology: low yields, energy intensive, dilute solutions, cost of
product recovery
9
Esa Aittomäki
2.6.2016
Finnish economical environment
 Industry already uses biotechnology: food, feed, chemicals, pulp
& paper, energy
 Extended raw material sourcing: forest based underutilized
streams, industrial side streams, C1 compounds (methanol, CO,
CO2), agricultural based: straw, grass, manure
 New bio based products: proteins, polymers, other chemicals,
functional food additives and supplements, improved antibioticfree feed
 New technology platforms: fractionation of lignocelluloses,
improved fermentation concepts, product recovery techniques
 New biocatalyst development: enzymes, whole cells
 Development of tools for biotechnology to speed-up: SynBio,
Bio ICT, speeding-up the microbial strain and protein engineering
10
Esa Aittomäki
2.6.2016
How to jump over hurdles?
 Focus on low-cost feedstock
 Improve yields and catalysts performance
 Look for more valuable products over the whole
concept
CO
H2
Sugar
11
CO2
CH3OH
CH4
New routes
Improved yields
Better productivities
Esa Aittomäki
2.6.2016
Thank you for your attention!